Onconova Therapeutics, Inc. (ONTX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.58-0.25 (-6.53%)
At close: 4:00 PM EDT
People also watch:
OMEDCNATOGXIHTBXVSTM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close3.83
Bid0.00 x
Ask0.00 x
Day's Range3.53 - 3.85
52wk Range3.13 - 18.90
1y Target EstN/A
Market Cap22.7M
P/E Ratio (ttm)-0.60
Beta-0.18
Volume276,982
Avg Vol (3m)133,485
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube6 days ago

    ETF’s with exposure to Onconova Therapeutics, Inc. : August 19, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Onconova Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to ONTX-US. Comparing the performance and risk of Onconova Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
    Capital Cube7 days ago

    Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016

    Categories: Yahoo Finance Get free summary analysis Onconova Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Onconova Therapeutics, Inc. – Threshold Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc., Array BioPharma Inc., Spectrum Pharmaceuticals, Inc., Celgene Corporation, Cleveland BioLabs, Inc. and Baxter International Inc. (THLD-US, CYCC-US, ARRY-US, ... Read more (Read more...)

  • GlobeNewswire10 days ago

    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results

    NEWTOWN, Pa., Aug. 15, 2016-- Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate ...